just read that cognition therapeutics had their investor conference back in march and lisa ricciardi was presenting on their alzheimer's drug candidate. apparently they had some positive phase 2 data on this compound called zervimesine that they're working on for treating alzheimer's and lewy body dementia.

what caught my eye was that lisa ricciardi actually bought like 39k shares for around 30k herself right before the presentation. that's always interesting to see - when the ceo is putting their own money in. the presentation was supposed to be interactive too, so investors could ask questions in real time.

looking at the insider activity, lisa ricciardi's purchase was basically the only move from insiders in the past 6 months which is a bit unusual. on the flip side, institutional investors seem pretty split - 15 added shares but 25 actually reduced their positions in that quarter. voss capital added a decent chunk though.

the company's focused on neurodegenerative stuff which is a tough space honestly. but if the phase 2 data on zervimesine holds up, could be something. hard to tell from a distance though. you following any biotech plays right now?